Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Novavax. For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded ...

Gaithersburg, MD-based Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company has also developed proprietary immune ...

Novavax Inc. closed 60.53% below its 52-week high of $17.81, which the company reached on July 26th.

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Novavax (NASDAQ:NVAX) shares fell on Tuesday after Citi started its coverage of the COVID shot maker with a Sell recommendation and a price target of $6, citing among other issues concerns over the ...

US biotech Novavax (Nasdaq: NVAX) has reported that its experimental combination COVID-19 and influenza vaccine generated ...

Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...

Victoria’s Secret (NYSE: VSCO) stock rose 0.4% after the lingerie retailer, reaffirmed its full-year sales guidance and ...